Lung Cancer
News and reporting on lung cancer.
Guardant Health Begins SHIELD Trial for Lung Cancer Early Detection
The company will enroll 10,000 high-risk patients in the trial and evaluate the ability of its SHIELD blood test to detect lung cancer early.
FDA Clears Jubilant Therapeutics' IND Allowing for LSD1/HDAC6 Inhibitor Clinical Trial
The company will evaluate JBI-802 in solid tumors, including small cell lung cancer and treatment-induced neuroendocrine prostate cancer.
Nuvalent Begins Study of ROS1 Inhibitor in Advanced NSCLC, Solid Tumors
The firm has designed the agent to overcome resistance to currently available ROS1 inhibitors and to treat cancers that have metastasized to the brain.
Novartis, BeiGene Ink Licensing Deal for TIGIT Inhibitor Ociperlimab
Novartis will pay BeiGene $300 million upfront for rights to develop and commercialize the agent, which BeiGene is studying with a checkpoint inhibitor in NSCLC and solid tumors.Â
Lyell Immunopharma Receives IND Clearance for Phase I Trial of CAR T-Cell Therapy for ROR1-Expressing TNBC, NSCLC
The company hopes to begin screening patients for ROR1 expression in the first quarter of 2022 and report initial data in 2023.